Financial Statement for 2002
Financial Statement, 1 January - 31 December 2002 · MIV-606 (now RP-606) outlicensed to Reliant Pharmaceuticals in February · MV026048 outlicensed to Roche in April · MIV-310 achieved positive clinical results against multiresistant HIV · MIV-210 against HIV and hepatitis B, as well as cathepsin S in immunological diseases, produced positive preclinical results · In December, Medivir and Paradigm entered a three-year collaboration within protease research · The Board of Directors appointed Bo Öberg CEO in December, for the period 1 January to 1 March when Lars Adlersson takes up position as Medivir's CEO and President. · An Extraordinary General Meeting in December approved the 2002/2007 staff stock option plan · Profit after financial items amounted to SEK -64.2 (-139.4) m; net sales rose to SEK 256.3 (125.9) m · CCS achieved net sales gains to SEK 153.3 (126.4) m; operating profit was SEK 22.4 (16.4) m Forthcoming Financial Reports The Annual General Meeting will be on 29 April 2003 The First-quarter Interim Report 2003 will be published on 29 April 2003. The second-quarter Interim Report 2003 will be published on 9 July 2003. Medivir's financial reports are available from its Website, www.medivir.com as of these dates, under the 'Financial Information' heading. For more information, please contact: Bo Öberg, CEO and President, Tel: +46 (0)8 5468 3100 Rein Piir, CFO and VP, IR, tel: +46 (0)8 5468 3123 or +46 (0)70 853 7292 The Medivir Group Medivir is an innovative, specialist pharmaceuticals research and development corporation, located in Cambridge, UK and Huddinge, Sweden. Medivir's research is focused on developing new pharmaceutical substances based on proteases and polymerases as target enzymes. The group comprises Medivir AB, the subsidiaries Medivir UK Ltd. and CCS AB, plus second-tier subsidiaries CCS (UK) Ltd. and Nordic Care Sweden AB. Medivir has been quoted on the Stockholm Stock Exchange since 1996. Medivir's research portfolio includes projects against HIV, jaundice, shingles, cold sores, osteoporosis, RA (rheumatoid arthritis), asthma, MS (multiple sclerosis) and organ/transplantation rejection. Medivir has four projects in clinical development phases, two of which are entering phase III after completing phase II. One project is in phase I and one is in phase II. Medivir's preclinical research encompasses a number of projects, one of which is in late preclinical development, one is entering, and one is in, the optimization phase and one is in the model substance identification phase. Additionally, Medivir has some fifteen activities in explorative phases. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/02/14/20030214BIT00620/wkr0001.doc The Full Report